Interestingly, our NSCLC cohort data validate studies showing high rates of ASS1 loss in non‐epithelioid mesothelioma, where p53 mutations have been identified to the exclusion of epithelioid mesothelioma, and underlie similar poor outcomes to platinum–pemetrexed chemotherapy.42, 43. Here, TP53 is linked to non-small cell lung carcinoma.